|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4861719A
(en)
|
1986-04-25 |
1989-08-29 |
Fred Hutchinson Cancer Research Center |
DNA constructs for retrovirus packaging cell lines
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US5094941A
(en)
*
|
1987-12-31 |
1992-03-10 |
Zymogenetics, Inc. |
Monoclonal antibodies to PDGF
|
|
US5278056A
(en)
|
1988-02-05 |
1994-01-11 |
The Trustees Of Columbia University In The City Of New York |
Retroviral packaging cell lines and process of using same
|
|
EP0428534B1
(en)
|
1988-06-14 |
1995-03-29 |
Cetus Oncology Corporation |
Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5670488A
(en)
|
1992-12-03 |
1997-09-23 |
Genzyme Corporation |
Adenovirus vector for gene therapy
|
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
|
JPH07501451A
(ja)
|
1991-11-25 |
1995-02-16 |
エンゾン・インコーポレイテッド |
多価抗原結合タンパク質
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
CA2156725A1
(en)
|
1993-02-22 |
1994-09-01 |
Warren S. Pear |
Production of high titer helper-free retroviruses by transient transfection
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
FR2712812B1
(fr)
|
1993-11-23 |
1996-02-09 |
Centre Nat Rech Scient |
Composition pour la production de produits thérapeutiques in vivo.
|
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
|
IL116816A
(en)
|
1995-01-20 |
2003-05-29 |
Rhone Poulenc Rorer Sa |
Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
DE69833755T2
(de)
|
1997-05-21 |
2006-12-28 |
Biovation Ltd. |
Verfahren zur herstellung von nicht-immunogenen proteinen
|
|
WO1998056915A2
(en)
|
1997-06-12 |
1998-12-17 |
Research Corporation Technologies, Inc. |
Artificial antibody polypeptides
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
EP1176195B1
(en)
|
1999-04-09 |
2013-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
AU2001276842B2
(en)
|
2000-06-28 |
2007-04-26 |
Glycofi, Inc. |
Methods for producing modified glycoproteins
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
WO2003026577A2
(en)
|
2001-09-24 |
2003-04-03 |
Seattle Genetics, Inc. |
P-amidobenzylethers in drug delivery agents
|
|
US20030157108A1
(en)
|
2001-10-25 |
2003-08-21 |
Genentech, Inc. |
Glycoprotein compositions
|
|
US7771951B2
(en)
|
2001-12-03 |
2010-08-10 |
Amgen Fremont Inc. |
Antibody categorization based on binding characteristics
|
|
DK1545613T3
(da)
|
2002-07-31 |
2011-11-14 |
Seattle Genetics Inc |
Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
|
|
CN107213469A
(zh)
|
2003-11-06 |
2017-09-29 |
西雅图基因公司 |
能够与配体偶联的单甲基缬氨酸化合物
|
|
EP1718667B1
(en)
|
2004-02-23 |
2013-01-09 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
JP4942643B2
(ja)
|
2004-03-02 |
2012-05-30 |
シアトル ジェネティックス， インコーポレイテッド |
部分的に付加された抗体およびそれらの結合体化方法
|
|
EP1626059A1
(en)
|
2004-08-09 |
2006-02-15 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
|
|
EP3505191A1
(en)
|
2004-11-12 |
2019-07-03 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the n terminus
|
|
JP4658125B2
(ja)
|
2005-06-28 |
2011-03-23 |
パイオニア株式会社 |
放送受信装置、妨害検出装置および妨害検出方法
|
|
DK1912671T3
(da)
|
2005-07-18 |
2017-11-27 |
Seattle Genetics Inc |
Beta-glucuronid-linker-lægemiddelkonjugater
|
|
EP1880729A1
(en)
|
2006-07-20 |
2008-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of soluble CD160 to suppress immunity
|
|
CL2007003291A1
(es)
*
|
2006-11-15 |
2008-07-04 |
Medarex Inc |
Anticuerpo monoclonal humano aislado que enlaza la proteina btla o fragmentos del mismo; acido nucleico que lo codifica; metodo de produccion; composicion e inmunoconjugado que los comprende; y metodo para inhibir el crecimiento de celulas de tumor e
|
|
EP2006299A1
(en)
|
2007-06-18 |
2008-12-24 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Identification of new isoforms of the MHC-class I specific receptor CD160 and uses thereof
|
|
EP2210903A1
(en)
*
|
2009-01-21 |
2010-07-28 |
Monoclonal Antibodies Therapeutics |
Anti-CD160 monoclonal antibodies and uses thereof
|
|
WO2011116276A2
(en)
*
|
2010-03-18 |
2011-09-22 |
Matthew Delisa |
Engineering correctly folded antibodies using inner membrane display of twin-arginine translocation intermediates
|
|
ES2606627T3
(es)
*
|
2010-05-28 |
2017-03-24 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Anticuerpos específicos anti-CD160 para el tratamiento de trastornos oculares basados en la neoangiogénesis
|
|
CA2813411C
(en)
|
2010-11-05 |
2016-08-02 |
Rinat Neuroscience Corporation |
Engineered polypeptide conjugates and methods for making thereof using transglutaminase
|
|
WO2013072714A1
(en)
*
|
2011-11-15 |
2013-05-23 |
Centre National De La Recherche Scientifique (Cnrs) |
Antibodies for molecular imaging of vulnerable plaques in atherosclerosis
|
|
US20180030135A1
(en)
|
2015-01-16 |
2018-02-01 |
Inserm (Institut National De La Santé Et De La Recherché Médicale) |
Human monoclonal antibodies against orexin receptor type 1
|